Stockscreener 앱 받기
40.53
0.93%
-0.38
전일 마감가:
$40.91
열려 있는:
$41.23
하루 거래량:
495.14K
Relative Volume:
0.59
시가총액:
$1.82B
수익:
-
순이익/손실:
$-47.20M
주가수익비율:
-25.89
EPS:
-1.5653
순현금흐름:
$-43.65M
1주 성능:
+28.02%
1개월 성능:
+46.05%
6개월 성능:
+226.07%
1년 성능:
+284.54%
1일 변동 폭
$39.70
$42.00
1주일 범위
$31.58
$44.89
52주 변동 폭
$4.8069
$44.89
Mbx Biosciences Inc Stock (MBX) Company Profile
명칭
Mbx Biosciences Inc
전화
(317) 989-3100
주소
11711 N. MERIDIAN STREET, CARMEL
MBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
40.53 | 1.84B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 개시 | Goldman | Sell |
| 2025-11-04 | 개시 | TD Cowen | Buy |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-08-15 | 재개 | Jefferies | Buy |
| 2025-08-05 | 개시 | Mizuho | Outperform |
| 2025-07-16 | 개시 | Oppenheimer | Outperform |
| 2025-04-10 | 개시 | Citizens JMP | Mkt Outperform |
| 2024-10-08 | 개시 | Guggenheim | Buy |
| 2024-10-08 | 개시 | JP Morgan | Overweight |
| 2024-10-08 | 개시 | Jefferies | Buy |
| 2024-10-08 | 개시 | Stifel | Buy |
모두보기
Mbx Biosciences Inc 주식(MBX)의 최신 뉴스
Guggenheim raises MBX Biosciences stock price target on obesity drug potential - Investing.com
MBX Biosciences Surges Amid Strategic Partnership Developments - timothysykes.com
Breakout Watch: What makes MBX Biosciences Inc stock attractive to growth fundsEarnings Summary Report & Real-Time Buy Zone Alerts - Bộ Nội Vụ
Stifel reiterates Buy rating on MBX Biosciences stock, citing obesity drug pipeline - Investing.com Canada
Stifel reiterates Buy rating on MBX Biosciences stock, citing obesity drug pipeline By Investing.com - Investing.com Nigeria
MBX Biosciences (NASDAQ:MBX) Trading 7.6% HigherTime to Buy? - MarketBeat
MBX Biosciences Sees Shares Surge amid Strategic Partnerships - timothysykes.com
MBX Biosciences Highlights 2026 Outlook and Pipeline Progress - TipRanks
Portfolio Shifts: Is MBX Biosciences Inc stock influenced by commodity pricesJuly 2025 Earnings & Fast Moving Trade Plans - baoquankhu1.vn
Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026 - TradingView — Track All Markets
Drug maker maps out once-monthly obesity shots and hormone disorder trial - Stock Titan
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% - MSN
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
MBX Biosciences (NASDAQ:MBX) Rating Increased to Strong-Buy at UBS Group - MarketBeat
Will MBX Biosciences Inc. stock benefit from upcoming earnings reports2025 Bull vs Bear & Real-Time Buy Zone Alerts - Улправда
Is MBX Biosciences Inc. stock positioned well for digital economyEarnings Growth Summary & High Yield Equity Trading Tips - Улправда
Will MBX Biosciences Inc. stock recover faster than marketJuly 2025 Sector Moves & Real-Time Market Trend Scan - Улправда
MBX Surge: Is It the Right Time? - timothysykes.com
MBX Biosciences (NASDAQ:MBX) Shares Gap UpTime to Buy? - MarketBeat
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Will MBX Biosciences Inc. stock attract ESG investors2026 world cup usa national team third place match star players set piece tactics match prediction tactical review - ulpravda.ru
UBS initiates coverage on MBX Biosciences stock with Buy rating By Investing.com - Investing.com Australia
UBS initiates coverage on MBX Biosciences stock with Buy rating - Investing.com
MBX Biosciences (NASDAQ:MBX) Trading Down 8.4%Here's Why - MarketBeat
Power Grid Corporation of India Limited Forms Bullish Flag Upside AheadGlobal Trade Effects & Free Trading Psychology Coaching - earlytimes.in
Commit To Purchase Mbx Biosciences At $20, Earn 25% Using Options - Nasdaq
MBX Biosciences (NASDAQ:MBX) Stock Price Down 5.8%Here's What Happened - MarketBeat
MBX Biosciences initiated with a sell at Goldman Sachs - MSN
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month HighStill a Buy? - MarketBeat
Mbx Biosciences stock hits all-time high of 34.85 USD By Investing.com - Investing.com Nigeria
MBX Biosciences (NASDAQ:MBX) Stock Price Up 10.8%Still a Buy? - MarketBeat
Mbx Biosciences stock hits all-time high of 34.85 USD - Investing.com
MBX Biosciences price target raised to $50 from $45 at Stifel - MSN
Take Profit: Will MBX Biosciences Inc stock keep outperforming rivalsJuly 2025 Pullbacks & Capital Efficiency Focused Ideas - moha.gov.vn
MBX Biosciences, Inc.(NasdaqGS:MBX) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) added to NASDAQ Biotechnology Index - marketscreener.com
Dip Buying: Will MBX Biosciences Inc stock keep outperforming rivalsJuly 2025 Intraday Action & Stock Portfolio Risk Control - moha.gov.vn
MBX Biosciences (NASDAQ:MBX) Upgraded at Wall Street Zen - MarketBeat
How sustainable is MBX Biosciences Inc. stock dividend payoutPortfolio Profit Report & Safe Entry Point Alerts - Улправда
Stifel maintains MBX Biosciences (MBX) buy recommendation - MSN
MBX Biosciences stock price target raised to $50 by Stifel on strong trial data By Investing.com - Investing.com Nigeria
Stifel Maintains MBX Biosciences (MBX) Buy Recommendation - Nasdaq
MBX Biosciences stock price target raised to $50 by Stifel on strong trial data - Investing.com South Africa
Aug Technicals: Will MBX Biosciences Inc. stock attract ESG investorsMarket Activity Recap & AI Enhanced Trading Alerts - Улправда
Is MBX Biosciences Inc. stock undervalued vs historical averagesJuly 2025 Sector Moves & High Accuracy Trade Signal Alerts - Улправда
Mbx Biosciences Inc (MBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):